Explore BioBoost LabsEpithalon (Epitalon)
A synthetic four-amino-acid peptide modelled on a pineal-gland extract, associated with a single research group’s longevity and telomerase claims.
What the name means
“Epithalon” (also spelled Epitalon) is derived from epithalamin, a peptide preparation extracted from the pineal gland.
The pineal gland sits in the epithalamus region of the brain. Epithalamin was a crude pineal extract; Epithalon is the short, defined synthetic peptide developed to represent its proposed active core.
What it actually is
Epithalon is a synthetic tetrapeptide — four amino acids joined by three peptide bonds.
The sequence is Ala-Glu-Asp-Gly (AEDG). Reference databases give a molecular formula of C₁₄H₂₂N₄O₉ and a mass near 390 g/mol, making it one of the smallest peptides in this batch.
Where it came from
Epithalon is associated with Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia.
It is part of a broader “peptide bioregulator” programme that began with organ extracts (here, pineal epithalamin) and worked toward short defined peptide sequences. This single-group lineage is important context for weighing the evidence.
Why it was created — the thought process
Pineal extracts had been reported to affect neuroendocrine regulation and aging markers in animal work by this group.
The design logic was to identify the shortest peptide sequence that could reproduce those reported effects, making a defined, synthesisable molecule instead of a crude extract. It was subsequently hypothesised to influence telomerase activity and gene expression.
How it is made
Epithalon is produced by solid-phase peptide synthesis (SPPS).
As a four-residue peptide it is comparatively simple to assemble; it is purified by HPLC and confirmed by mass spectrometry.
What the research actually shows — honestly
The most striking claims about Epithalon — telomerase activation and extension of lifespan — come largely from a small body of work centred on one research group.
That work includes rodent studies and some limited human reports, but it has not been independently replicated at scale, and the wider scientific community treats the longevity claims with caution. Epithalon has no FDA or EMA approval.
It should be read as a research compound with unusually concentrated, unreplicated evidence — not a proven anti-aging agent. No medical advice or administration guidance is offered here.
Selected research & sources
The items below are drawn from the peer-reviewed literature (PubMed) and describe results observed in research models or reported in the clinical literature. They are listed so the evidence can be examined at its source — not to suggest any use.
- Khavinson V, et al. Molecules. 2020. “AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism.” doi.org/10.3390/molecules25030609
- Khavinson VKh, et al. Bull Exp Biol Med. 2017. “Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland.” doi.org/10.1007/s10517-017-3922-8
- Khavinson VKh, et al. Bull Exp Biol Med. 2011. “Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture.” doi.org/10.1007/s10517-011-1473-y
- Linkova NS, et al. Bull Exp Biol Med. 2011. “Peptidergic stimulation of differentiation of pineal immune cells.” doi.org/10.1007/s10517-011-1470-1
Regulatory status: Not FDA-approved; no recognized human indication. Research material, RUO.
◆ A reference, not a recommendation
This page explains what Epithalon (Epitalon) is and where it came from — the science and the story — not who should use anything, or how. These are research materials for laboratory research only; nothing here is medical, dosing, or treatment advice.
Research-use-only educational content. Factual overview; claims of clinical benefit are not implied.